Cibus (CBUS) Q3 2026 earnings review
Cibus cuts its lab costs, but cash runs low
Cibus cut its lab spending again and moved its rice traits into customer fields, but its cash balance is nearly gone. The gene-editing company burned $9 million in operating cash during the third quarter, leaving $11 million in the bank to fund operations into early 2027. Chief executive Craig Wichner raised the peak biofragrance revenue target to $100 million by switching from royalties to direct product sales, while keeping the year-end cash burn plan unchanged.
| Revenue | $800K +30% from a year ago, -20% from last quarter |
|---|---|
| Operating cash used | $9.3M 9-month burn down 19% from a year ago |
| Cash and cash equivalents | $10.7M funds operations into early Q1 2027 |
| Year-end cash burn outlook | Unchanged ~$35M annual pace (~$8.8M in Q4 by our math) |
⚖️ Verdict: 🔴 Bearish
The story got worse because the cash clock is down to one quarter while near-term commercial orders and launch dates slipped again. Upfront partner balances dropped to almost zero, second-half biofragrance scale-up orders have not arrived, and the US rice launch target loosened from 2029 to 2029 or 2030. On the positive side, partner Interoc planted Cibus's rice traits in Ecuador and Crystal Crop Protection began paying for mustard research in India.
The question now is whether Cibus can secure non-dilutive partner cash before it has to sell more stock in a few months. Either biofragrance scale-up orders and a binding Interoc contract bring in upfront cash, or the company must rely on heavy share issuance to stay afloat. Fourth-quarter financing disclosures and first-quarter Ecuador trial results will settle it.
🐂 Bull Case
Lab Closures and Layoffs Cut Cash Burn
Cibus edits plant genes for seed companies and develops bio-based ingredients, and it is cutting expenses to stretch its cash. The company closed its Oberlin lab, wound down its Roseville, Minnesota site, and consolidated lab work into San Diego. Those actions reduced research and development spending by 26.6% from a year ago to $7.9 million, cutting research costs by 764 percentage points of revenue by our math.
- Research personnel costs: down $1.5 million from a year ago after staff cuts
- Lab facility costs: down $0.9 million after closing Oberlin and Roseville
- Nine-month operating cash burn: $30.2 million, down 18.8% from $37.2 million last year
- Selling, general, and administrative costs: $5.4 million, up 2.4% on equipment moving fees
What to watch: fourth-quarter operating cash burn against the $8.8 million implied by our math from the year-end target. Holding below that level will show whether the San Diego consolidation keeps expenses down without further layoffs.
Interoc Plants Rice Trials as Mustard Starts
"Our Rice traits performed well in Latin American field trials and are now being tested where it counts, in our customer Interoc's own varieties in its own fields," chief executive Craig Wichner said. HT1 and HT3 are Cibus's gene edits that help rice crops survive weed-killing sprays. Latin American partner Interoc planted those traits in Ecuador in late September, while England approved field trials for pod-shatter canola.
The company also signed Crystal Crop Protection in September to develop gene-edited mustard in India and began billing for that research during the third quarter. That matters because partner payments fund daily lab work today while rice royalties remain years away. What to watch: field trial results from Interoc's Ecuador rice planting in the first quarter of 2027, which must succeed to convert Interoc's letter of intent into a commercial contract.
🐻 Bear Case
Cash Runs Out Early Next Year
Cibus needs fresh funding within months to stay open. The gene-editing group finished September with $10.7 million in cash and burned $9.3 million in operating cash during the third quarter. Management said its cash will last only "into early in the first quarter of 2027" before counting any new financing, which leaves just one quarter of breathing room at the current spending pace.
At the same time, deferred revenue — cash partners have paid upfront for research work not yet performed — dropped from $627 thousand in June to $7 thousand in September. Accounts receivable also fell from $838 thousand to zero. Because upfront partner balances are now empty, near-term cash inflows depend on new billings and grants, forcing Cibus to issue more stock or strike a financing deal before winter ends.
What to watch: new equity sales or partner upfront payments disclosed in the fourth-quarter report. Without a cash infusion before early first quarter 2027, the business cannot fund its planned operations.
Biofragrance Target Triples While Initial Orders Wait
Cibus develops yeast-fermented scents for a consumer-products partner under its Sustainable Ingredients program. This quarter the company raised its estimated peak annual revenue for biofragrances from $20–40 million to $100 million across eight potential products. Management said the higher figure reflects a "direct-sales model rather than the previously-assumed royalty model", and it started the manufacturing process while the partner requested larger test samples of two newer scents.
Switching to direct sales raises the top-line number because Cibus records the full product price instead of a royalty cut, but it also requires Cibus to pay for manufacturing. Meanwhile, the milestone table reveals that expected second-half scale-up orders for the first two approved scents are "not yet received". Raising long-term revenue targets while near-term commercial orders wait cuts against Wichner's claim that revenue-generating programs moved closer.
What to watch: signed scale-up orders for the initial two biofragrances in the fourth-quarter update. Missing that year-end window would delay the only product line expected to bring near-term commercial cash.
US Rice Launch Slips as Customers Stall
Cibus licenses its weed-control rice traits to seed companies and earns royalties only after farmers buy and plant the seed. In the United States, the launch is "paired with Albaugh's herbicide-registration timeline, and current planning targets a 2029 or 2030 U.S. launch". Three months ago management targeted 2029, and a year ago it targeted 2028, so the domestic timeline has slipped for a second time.
The company also kept its rice customer count at seven across the Americas for a fourth straight quarter, even though its 2026 milestone goals called for signing new rice seed partners this year. In canola, transferring edited seed lines to the John Innes Centre slipped from the third quarter into the fourth quarter. What to watch: a signed definitive commercial contract with Interoc before year-end 2026, which would lock in Latin American launch terms for 2028.
Risks this quarter didn't answer
Three standing financial and commercial risks received no new answers in the third-quarter release.
- Related-party royalty liability: grew to $263.4 million as non-cash interest added $9.8 million, pushing stockholders' equity to a $5.7 million deficit, with no disclosure of what share of future trait royalties goes to liability holders.
- Unproven royalty and scent pricing: Cibus still estimates $200 million in peak rice royalties across 5–7 million acres ($29–40 per acre by our math) without disclosing a contracted per-acre rate or biofragrance supply prices.
- European herbicide-tolerance exclusion: the new European Union gene-editing law excludes herbicide-tolerant crops from conventional breeding rules, leaving Cibus's weed-control traits out of its European regulatory opening.
👓 Other Themes
Cost Review Keeps Focus on Two Programs
Chief executive Craig Wichner completed his review of Cibus's cost structure and capital allocation, which management had promised to share this quarter. The company said the review reinforced its focus on Sustainable Ingredients and Rice "to structurally reduce its cost base" while keeping selective spending on fertilizer efficiency and crop disease resistance. The review brought no new restructuring charges and left the $35 million year-end cash burn target intact.
💲 Other KPIs
Sales rose 30.1% from a depressed $615 thousand a year ago, when partner research work slowed, but fell 19.5% from $994 thousand last quarter. Third-quarter revenue came from consumer-partner biofragrance work and the first billings under the new Indian mustard agreement with Crystal Crop Protection.
The balance owed to related parties for future royalty payments grew 16.8% from $225.5 million a year ago and rose $9.8 million from last quarter. Non-cash interest on this obligation made up 44.9% of Cibus's $21.9 million net loss in the third quarter by our math.
Share count rose 45.3% from 52.9 million a year ago after public stock offerings in January and March 2026 raised $31.8 million in net proceeds across the first nine months. The higher share count narrowed net loss per share by 34.1% to $0.29, even though net loss shrank only 6.8%.
🔮 Guidance
Unchanged. Management still plans to exit 2026 burning about $35 million of cash a year, after raising that target from $30 million last quarter. By our math, that exit pace equals about $8.8 million of quarterly cash burn in the fourth quarter, down from $9.3 million in the third quarter.
Unchanged. The plant-genetics group still expects its $10.7 million cash balance to fund planned operating expenses and capital spending into early in the first quarter of 2027. Because Cibus burned $9.3 million in the third quarter, the outlook leaves roughly three to four months of cash without a new stock sale.
❓ Key Questions
How will Cibus fund operations past early first quarter 2027?
Cash stood at $10.7 million on September 30 against a $9.3 million quarterly burn, and deferred revenue is down to $7 thousand. Investors need to know whether funding will come from stock sales or upfront partner cash.
What manufacturing costs come with direct biofragrance sales?
Switching biofragrances from royalties to direct sales lifted the peak revenue estimate from $20–40 million to $100 million. Management has not said how much working capital, contract manufacturing spend, or gross margin that direct model requires.
Why have second-half biofragrance scale-up orders not arrived yet?
The consumer partner approved the first two scents and Cibus started its manufacturing process, but the milestone table marks second-half scale-up orders as not yet received with only one quarter left in 2026.
What share of future royalties goes to related-party liability holders?
The related-party royalty liability reached $263.4 million and pushed stockholders' equity into a $5.7 million deficit. Management has not disclosed how future rice or biofragrance cash flows split between liability holders and common shareholders.